




The relative strengths and weaknesses of Scopus Biopharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Scopus Biopharma Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 7.1% points. The greatest weakness of Scopus Biopharma Inc is the variable Assets, reducing the Economic Capital Ratio by 132% points.

The company's Economic Capital Ratio, given in the ranking table, is 70%, being 205% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	8,185
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,170
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	-19
Other Expenses	0
Other Liabilities	0
Other Net Income	681
Other Revenues	0
Property and Equipment	2.8
Research and Development	15,023
Selling, General and Administrative Expense	12,611

Output Variable	Value in 1000 USD
Assets	8,188
Liabilities	4,170
Expenses	27,635
Revenues	0
Stockholders Equity	4,017
Net Income	-26,953
Comprehensive Net Income	-26,963
BaseVar	20,346
ECR before LimitedLiability	-295%
Economic Capital Ratio	70%